Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
about
Identification and characterization of a novel Plasmodium falciparum merozoite apical protein involved in erythrocyte binding and invasionProtection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesConstruction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9.Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.The ears of the African elephant: unexpected high seroprevalence of Plasmodium ovale and Plasmodium malariae in healthy populations in Western AfricaPlasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationNew candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).The use of transgenic parasites in malaria vaccine research.The generation and evaluation of two panels of epitope-matched mouse IgG1, IgG2a, IgG2b and IgG3 antibodies specific for Plasmodium falciparum and Plasmodium yoelii merozoite surface protein 1-19 (MSP1(19)).Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.Plasmodium falciparum MSP3 exists in a complex on the merozoite surface and generates antibody response during natural infection.A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
P2860
Q27230023-9798B4DD-881E-40D9-AF8D-70A373CFD1A5Q33356029-084770C3-FEE9-453C-883A-BB61DB10259DQ33499694-0813EA2F-BAB1-455E-86B1-CE9EF0F46AABQ33596284-B9033268-AD7B-4AF4-98AD-51CBCC817252Q33613937-A9932F82-A015-49D8-9DD2-695B756435A7Q33808057-2448C903-7643-46F7-9147-A272B2FD1795Q34119427-2A0AF321-DE26-456F-89EF-F436C8989F40Q34290768-E94D0194-C8AE-48A8-8F1A-D6C263AC9713Q35762375-1250DE71-0D23-4BDC-B1B2-73F9DEEB1AAAQ35945359-9F03F139-A564-4941-B87B-2415397A9828Q36640081-6F1C2B37-5C33-4357-BC1A-AD24CF23A699Q36785777-7F761758-FC5C-4E09-BCEC-59AC34434B08Q37425845-F8451147-1D80-4397-A47A-3F18671DD154Q39318510-49AF8CD5-D5F3-4A21-95F6-69E88206DA01Q39395136-2D4E9A3E-EB8A-47B5-B8FC-A09677CA7B41Q40752357-F0771906-A75A-4E58-A13D-F22A92AF5E01Q47964774-B2E3FDC0-266A-4DA5-BCEE-27910B3230FDQ47989426-519F8503-3169-4459-A557-9A98F49ED80AQ54212100-B18DBB6B-65C7-4C20-9FE1-11479D13E5AFQ55215825-144DCA6B-9CFA-4D26-BE20-23289A4A970E
P2860
Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Immunogenicity and protective ...... um merozoite surface protein-1
@nl
Immunogenicity and protective ...... ng human compatible adjuvants.
@en
type
label
Immunogenicity and protective ...... um merozoite surface protein-1
@nl
Immunogenicity and protective ...... ng human compatible adjuvants.
@en
prefLabel
Immunogenicity and protective ...... um merozoite surface protein-1
@nl
Immunogenicity and protective ...... ng human compatible adjuvants.
@en
P2093
P1433
P1476
Immunogenicity and protective ...... ng human compatible adjuvants.
@en
P2093
Anju Katyal
Asif Mohmmed
Palakodeti V N Dasaradhi
Pawan Malhotra
Suraksha Sachdeva
P304
P356
10.1016/J.VACCINE.2005.11.041
P407
P577
2005-12-06T00:00:00Z